标题:Th22 and related cytokines in inflammatory and autoimmune diseases
作者:Tian,T.;Yu,S.;Ma,D.
作者机构:[Tian, T] Shandong University, Qilu Hospital, Department of Hematology, 107 WenhuaXi Road, Jinan 250012, China;[ Yu, S] Shandong University, Qilu Hosp 更多
通讯作者:Ma, DX
通讯作者地址:[Ma, DX]Shandong Univ, Qilu Hosp, Dept Hematol, 107 WenhuaXi Rd, Jinan 250012, Peoples R China.
来源:Expert opinion on therapeutic targets
出版年:2013
卷:17
期:2
页码:113-125
DOI:10.1517/14728222.2013.736497
关键词:IL-22;Inflammatory and autoimmune diseases;Th22;Therapeutic perspectives
摘要:Introduction: Th22 and related cytokines regulate various processes and have been linked to diverse effects. The levels of Th22 and cytokine IL-22 are increased in several disorders and positively related to some autoimmune diseases. Preclinical studies have suggested that the inhibition or stimulation of IL-22 is an attractive approach to reverse the immune disorders. Simultaneously, considering many patients with refractory autoimmune diseases respond poorly to the therapies which are highly toxic, more effective therapies are to be examined. Areas covered: The role of Th22 cells and related cytokines and therapeutic strategies targeting them in many illnesses, especially inflammatory and autoimmune diseases. Expert opinion: Th22 cells and related cytokine IL-22 regulate multiple biological functions and play an important role in a number of inflammatory and autoimmune diseases. They have unique and attractive advantages for targeting. Targeting IL-22 has already been trialed in many mice experiments, showing better efficacy and fewer side effects compared with classical drugs. Targeting IL-22 or Th22 might provide pathogenetic treatment. However, Th22 subset is a recently identified Th subset and its associated research is extremely limited. Therefore, there are still many unanswered questions and further researches are warranted.
收录类别:SCOPUS;SCIE
WOS核心被引频次:23
Scopus被引频次:23
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872242880&doi=10.1517%2f14728222.2013.736497&partnerID=40&md5=e8cf4c859c5fde741c2df5384c46b1f3
TOP